{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-021219","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.247110+00:00","generated_at":"2026-06-01T01:24:35.929482+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024","bullets":["Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.","Trial cost estimated at ~$1.5M; led by Prof. Catherine Cluver (Stellenbosch Univ.) with collaboration from Prof. Stephen Tong (Univ. Melbourne).","DM199 did not cross the placental barrier in rat studies; prior REDUX CKD data showed SBP reduction of 12.6 mmHg (p=0.004) in patients with baseline SBP ≥140 mmHg.","No approved therapeutics for preeclampsia in US/Europe; DM199 is a large-molecule protein (rhKLK1) that may improve placental perfusion and reduce hypoxia.","Company to host KOL event on July 29, 2024; conference call on June 27, 2024 at 8:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-021219","json":"https://secwatch.observer/filing/0001437749-24-021219.json","markdown":"https://secwatch.observer/filing/0001437749-24-021219.md","text":"https://secwatch.observer/filing/0001437749-24-021219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/0001437749-24-021219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/dmtp20240624_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:24:35.929482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}